AASLD2019[461]慢性乙型肝炎的血清HBCRAG谱 一线口服抗病毒药物

StephenW

461
SERUM HBCRAG PROFILES IN CHRONIC HEPATITIS B
PATIENTS TREATED WITH FIRST-LINE ORAL ANTIVIRAL
THERAPY
Lung Yi Mak1, Danny Ka Ho Wong1,2, Wai-Kay Seto1,2, James
Fung1,2, Ching Lung Lai2,3 and Man Fung Yuen1,3, (1)Medicine,
The University of Hong Kong, (2)State Key Laboratory of Liver
Research, The University of Hong Kong, (3)The University of
Hong Kong, Hong Kong
Background: Serum hepatitis B core-related antigen
(HBcrAg) is a potential surrogate marker for intra-hepatic
covalently-closed circular DNA in chronic hepatitis B (CHB)
We aimed to study the profiles of serum HBcrAg in CHB
patients treated with first-line oral nucleos(t)ide analogues
(NA): entecavir (ETV), tenofovir disoproxil fumarate (TDF)
or tenofovir alafenamide (TAF) Methods: Serum HBcrAg
was measured in 264 NA-treated CHB patients (ETV: TDF:
TAF = 197: 30: 37) using the Lumipulse G HBcrAg assay in a
Lumipulse G1200 analyzer (Fujirebio Inc, Toyko, Japan) with
a lower detection limit of 100 units per milliliter (U/ml) The
values of HBcrAg were log transformed and were expressed
in log U/mL Serum HBcrAg levels were measured at baseline,
48-week and 96-week of NA therapy Results: Among the
264 patients, 130 (49 2%) were hepatitis B e antigen (HBeAg)
positive In this interim report, HBcrAg level measurements
were completed for all 3 groups of patients at baseline and
week 48 and for TDF and TAF treated patients at week 96 All
3 first-line NAs led to significant decline of serum HBcrAg at
48-week compared to baseline (ETV: 1.97 vs. 3.02, TDF: 2.88
vs. 4.49, and TAF: 3.00 vs. 4.36, respectively; all p <0.001).
For TDF and TAF, further decline of HBcrAg was observed at
96-week compared to 48-week (TDF: 2.09 vs. 2.88, and TAF
1.89 vs. 3.00, respectively; both p<0.01) [figure]. However,
when only HBeAg-negative patients were analyzed, the
drop in HBcrAg at 96-week compared to 48-week was not
significant for both TDF and TAF treated patients (0.62 vs.
1.08 and 0.56 vs. 0.80, respectively; both p>0.05). There
were no significant differences for the magnitude of HBcrAg
decline at 48-week between the 3 different types of NAs (ETV:
1.088; TDF: 1.437; TAF: 1.318; p>0.05 for all 3 comparisons).
Similarly, TDF and TAF produced no significant differences in
the magnitude of HBcrAg decline at 96-week (2 20 vs 1 74,
p>0.05). Conclusion: The 3 first-line NAs showed similar
potencies in suppression of viral activity upon 1 year duration
of therapy. The lack of significant drop of HBcrAg in HBeAgnegative
patients reflects the limited utility of this marker in
HBeAg-negative phase.

StephenW

461
慢性乙型肝炎的血清HBCRAG谱
一线口服抗病毒药物治疗的患者
治疗
麦龙宜1，丹尼嘉豪皇1,2，怀凯·濑户1,2，詹姆斯
Fung1,2，Ching Lung Lai2,3和Man Fung Yuen1,3，（1）Medicine，
香港大学（2）肝病国家重点实验室
香港大学研究（3）
香港香港
背景：血清乙肝核心相关抗原
（HBcrAg）是肝内潜在的替代指标
慢性乙型肝炎（CHB）中共价闭合的环状DNA
我们旨在研究CHB中血清HBcrAg的概况
一线口服核苷酸类似物治疗的患者
（NA）：恩替卡韦（ETV），替诺福韦富马酸二甲酚（TDF）
或Tenofovir alafenamide（TAF）方法：血清HBcrAg
在264名接受NA治疗的CHB患者中进行了测量（ETV：TDF：
TAF = 197：30：37），使用Lumipulse G HBcrAg分析
Lumipulse G1200分析仪（日本Toyko，Fujirebio Inc）
最低检测限为每毫升100个单位（U / ml）
将HBcrAg值进行log转换并表达
在基线时以log U / mL的对数测定血清HBcrAg水平，
NA治疗48周和96周的结果：
264例患者，其中130例（49 2％）是乙型肝炎e抗原（HBeAg）
阳性在本中期报告中，HBcrAg水平测量
在基线和所有3组患者中均已完成
第48周以及在第96周接受TDF和TAF治疗的患者
3个一线NAs导致血清HBcrAg显着下降。
与基准相比48周（ETV：1.97对3.02，TDF：2.88
vs. 4.49和TAF：分别为3.00和4.36；所有p <0.001）。
对于TDF和TAF，观察到HBcrAg进一步下降。
96周与48周相比（TDF：2.09对2.88，以及TAF
1.89和3.00；均p <0.01）[图]。然而，
当仅对HBeAg阴性患者进行分析时，
与第48周相比，第96周的HBcrAg下降没有
对TDF和TAF治疗的患者均显着（0.62 vs.
分别为1.08和0.56与0.80；两者均p> 0.05）。那里
HBcrAg量无明显差异
3种不同类型的NA之间在48周时下降（ETV：
1.088; TDF：1.437； TAF：1.318;对于所有3个比较，p> 0.05）。
同样，TDF和TAF在
96周时HBcrAg下降的幅度（2 20比1 74，
p> 0.05）。结论：3个一线NA表现出相似
持续1年可抑制病毒活性
治疗。 HBcrAg阴性患者中HBcrAg缺乏明显下降
患者反映出该标记物在
HBeAg阴性阶段。